This is a case study to help you discover connections between the appreciation of art and the workplaces and other spaces that people inhabit.
The chief executive officer (CEO) of a pharmaceuticals company wants to invest in new architecture and art for the company headquarters. You have been chosen to recommend artwork for the new location. Review the following information in preparation for your work on the project:
- Company Profile and Project Overview
The vice president (VP) of human resources has asked you to develop some initial information in a report.
Answer the following questions keeping the project overview details in mind:
- What are 3 initial works, on the market, that you might suggest that the international company consider for acquisition or loan, and how much should the company budget for these works?
- What security considerations would you have to take into account?
- What are the business advantages of an art collection? How does “art appreciation” extend to the business and professional world?
For each of the 3 pieces, create a brief informational card that might also go into a brochure, explaining the following, in a condensed form:
- The subject of the work
- The biography of the artist
- The techniques and media used
- Some key interpretive, historical, or descriptive information about the piece
Be sure to address the following questions:
- How do the characteristics and style fit the organization and environment?
- Why might employees be interested in them?
Prepare your response as a report to the VP, using Word. Include photos of the recommended pieces of art. Be sure to include citations and references as needed, although it is not necessary to format this as an APA document.
| Company Profile
• Founded 1975, Milwaukee, Wisconsin
• 22,000 employees worldwide
• Principal Products:
o Orfin, a blood pressure drug
o Manfer, a drug to treat neuropathy, often associated with diabetes
• Company Motto: “Dum inter homines sumus, colamus humanitatem” (Seneca)
Worldwide Pharmaceuticals (WP), based in Milwaukee, Wisconsin, has experienced tremendous growth and profitability since 2010. It has gained a strong reputation for its products. Its profits have grown from two types of organic drugs that it has developed, as well as from new products that it has acquired along with a smaller pharmaceutical laboratory. Altogether, the growth has meant that the company has evolved into a collection of buildings and locations that have been haphazardly scattered over the city and its suburbs. In addition to the headquarters operations, the company also has plants and sales offices across the United States, and in Europe and Asia.
The chief executive officer (CEO) wants to invest in new architecture for the company headquarters, and the company has located a site that is open, yet still convenient to commuters from other parts of the Milwaukee area. The new site will allow consolidation of headquarters operations, sales and marketing, along with some of the key research and development operations. Drug production itself will remain decentralized, with its own secure facilities elsewhere in Milwaukee and other cities. Some sales and marketing operations will also remain decentralized, but senior leadership for sales and marketing will be located in Milwaukee.
The new site is clean, and it does not have any existing building on it. WP will get to start from scratch and build its own facilities as it wants to. The CEO and senior leadership want a building that soars, and that features open spaces both in the lobby as well as in the office areas.